BridgeBio Pharma BBIO Change in Other Assets
Change in Other Assets at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's change in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's change in other assets?
- BridgeBio Pharma (BBIO) reported change in other assets of $18.85M in Q1 2026.
- How has BridgeBio Pharma's change in other assets changed year-over-year?
- BridgeBio Pharma's change in other assets increased by 3769.6% year-over-year, from $487K to $18.85M.
- What is the long-term trend for BridgeBio Pharma's change in other assets?
- Over 2 years (2021 to 2023), BridgeBio Pharma's change in other assets has grown at a -20.4% compound annual growth rate (CAGR), from $4.26M to $2.7M.
- What does change in other assets mean?
- The change in prepaid expenses and other miscellaneous short-term assets.
- How do you interpret change in other assets?
- An increase represents a cash outflow, often due to higher prepaid insurance, software licenses, or research-related deposits.
- How does change in other assets compare across companies?
- Standard across most corporate entities, reflecting administrative and operational overhead.